ReShape Lifesciences shares are trading higher after the company received a Notice of Allowance for its U.S. patent application titled "Intragastric Volume-Occupying Device and Method for Fabricating Same" for treating obesity.

7/3/24 1:01:16 PM ET

Medical/Dental Instruments

Health Care

Get the next $RSLS alert in real time by email

Get the next $RSLS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RSLS

Date	Price Target	Rating	Analyst
10/8/2021	$8.00	Buy	Maxim Group

More analyst ratings

$RSLS
Press Releases

Fastest customizable press release news feed in the world

ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
IRVINE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 17/046,677, entitled, "Simultaneous Multi-Site Vagus Nerve Modulation for Improved Glycemic Control System and Methods." When issued, the patent will provide protection until April 12, 2039. The Diabetes Neuromodulation system leverages its proprietary vagus nerve block (vBloc™) technology platform, along with vagus nerve stimulation, to treat Type 2 diabetes, a prominent disorder linked
3/10/25 8:31:00 AM ET
$RSLS
Medical/Dental Instruments
Health Care
ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX
IRVINE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that it has signed a distribution agreement with Liaison Medical for distribution of ReShape's next generation, enhanced Lap-Band® 2.0 FLEX and Tubing Kit, in Canada. "The signing of this distribution agreement in Canada, on the heels of the November 2024 approval by Health Canada for the Lap-Band® 2.0 FLEX, is a testament to our commitment to broadly launching this important product to improve the patient experience," stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences. "Initia
2/25/25 8:31:00 AM ET
$RSLS
Medical/Dental Instruments
Health Care
ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering
IRVINE, Calif., Feb. 15, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® ("ReShape" or the "Company") (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the pricing of its public offering of 2,575,107 units at a public offering price of $2.33 per unit. Each unit consists of one common share (or pre-funded warrant to purchase one common share in-lieu thereof) and one warrant to purchase one common share. The warrants, which are not exercisable unless and until approved by ReShape stockholders, will be initially exercisable at a price of $5.83 per share, subject to standard adjustments for dividends, splits and similar events, and als
2/15/25 11:17:53 PM ET
$RSLS
Medical/Dental Instruments
Health Care

$RSLS
Financials

Live finance-specific insights

ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the third quarter ended September 30, 2024, including a corporate update on Thursday, November 14, 2024, after market. Management will host a conference call on Thursday, November 14 at 4:30 pm ET, and will be joined by Krishna K. Gupta, a current Director of Vyome Therapeutics, who will be appointed Chairman of the combined company upon completion of the previously announced merger agreement between the two companies. A live webcast will be available on the
11/12/24 4:05:00 PM ET
$RSLS
Medical/Dental Instruments
Health Care
ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
IRVINE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the second quarter ended June 30, 2024, including a corporate update on Wednesday, August 14, 2024, after market. Management will host a conference call on August 15 at 4:30 pm ET, and will be joined by Krishna K. Gupta, a current Director of Vyome Therapeutics, who will be appointed Chairman of the combined company upon completion of the previously announced merger agreement between the two companies. A live webcast will be available on the "Events and Presenta
8/13/24 8:31:00 AM ET
$RSLS
Medical/Dental Instruments
Health Care
ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update
Commercial Launch of Next-Generation Lap-Band® 2.0 FLEX Continues Significant Reduction in Overall Operating Expenses of 51% in the First Quarter of 2024 Compared to the First Quarter of 2023 Implementation of 2024 Cost Reduction Plan Continues, Expected to Reduce Operating Expenses by 55.4% Compared to 2023 Conference Call to be Held at 4:30 pm ET Today IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the first quarter ended March 31, 2024 and provided a corporate strategic update. First Quarter 2024 and Subsequent Highlights Ma
5/15/24 4:05:00 PM ET
$RSLS
Medical/Dental Instruments
Health Care

ReShape Lifesciences Appoints Seasoned Sales and Marketing Executive, Nick Ansari, as Senior Vice President of Global Commercial Operations
SAN CLEMENTE, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the company has appointed Nick Ansari as Senior Vice President of Global Commercial Operations, effective September 6, 2022. Mr. Ansari, who, from 2014 to 2019 was Senior Vice President Global Sales for Enteromedics, the predecessor company to Reshape, will be responsible for strengthening the executional efficiencies of the sales and marketing team, worldwide. In this role, he will report directly to Mr. Paul F. Hickey, ReShape's President and Chief Executive Officer. "Nick is a proven executive
8/23/22 8:30:00 AM ET
$RSLS
Medical/Dental Instruments
Health Care
ReShape Lifesciences Announces Appointment of Paul F. Hickey as President and Chief Executive Officer
SAN CLEMENTE, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board of Directors has appointed Paul F. Hickey as President and Chief Executive Officer and as a member of the Board of Directors, effective August 15, 2022. Mr. Hickey succeeds Bart Bandy, who has separated from the company to pursue other opportunities. Thomas Stankovich, Chief Financial Officer of ReShape, will serve as Interim President and Chief Executive Officer until Mr. Hickey joins the company. Dan W. Gladney, current Chair of the Board of Directors, will assume a more active role as Exe
7/27/22 4:05:00 PM ET
$RSLS
Medical/Dental Instruments
Health Care
ReShape Lifesciences Strengthens Leadership Team with Appointment of Michael Bordainick as Senior Vice President, Commercial Operations
SAN CLEMENTE, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced the appointment of Michael Bordainick as its Senior Vice President, Commercial Operations. In this newly created role, as part of the Company's next phase of operational growth, Mr. Bordainick will be responsible for strengthening the strategic development and executional efficiencies of the sales and marketing teams. "As Michael brings significant experience and capabilities to advance ReShape's recently launched commercial programs, including direct-to-consumer marketing and enhanced support for o
1/13/22 8:30:00 AM ET
$RSLS
Medical/Dental Instruments
Health Care

ReShape Lifesciences shares are trading higher after the company received a Notice of Allowance for its U.S. patent application titled "Intragastric Volume-Occupying Device and Method for Fabricating Same" for treating obesity.

Chat with this insight

Recent Analyst Ratings for
$RSLS

$RSLS
Press Releases

Fastest customizable press release news feed in the world

ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX

ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering

$RSLS
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by ReShape Lifesciences Inc.

SEC Form SC 13D filed by ReShape Lifesciences Inc.

SEC Form SC 13D filed by ReShape Lifesciences Inc.

$RSLS
SEC Filings

SEC Form PRER14A filed by ReShape Lifesciences Inc.

SEC Form PRE 14A filed by ReShape Lifesciences Inc.

SEC Form SCHEDULE 13G filed by ReShape Lifesciences Inc.

$RSLS
Financials

Live finance-specific insights

ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update

$RSLS
Leadership Updates

Live Leadership Updates

ReShape Lifesciences Appoints Seasoned Sales and Marketing Executive, Nick Ansari, as Senior Vice President of Global Commercial Operations

ReShape Lifesciences Announces Appointment of Paul F. Hickey as President and Chief Executive Officer

ReShape Lifesciences Strengthens Leadership Team with Appointment of Michael Bordainick as Senior Vice President, Commercial Operations

$RSLS
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Maxim Group initiated coverage on Reshape Lifesciences with a new price target

$RSLS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Stankovich Thomas sold $39 worth of shares (172 units at $0.23), decreasing direct ownership by 0.75% to 22,777 units (SEC Form 4)

New insider Schneid Yair claimed ownership of 2,461,000 shares (SEC Form 3)

Stankovich Thomas sold $386 worth of shares (435 units at $0.89), decreasing direct ownership by 2% to 22,949 units (SEC Form 4)

ReShape Lifesciences shares are trading higher after the company received a Notice of Allowance for its U.S. patent application titled "Intragastric Volume-Occupying Device and Method for Fabricating Same" for treating obesity.

Chat with this insight

Recent Analyst Ratings for $RSLS

$RSLS Press Releases

Fastest customizable press release news feed in the world

ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX

ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering

$RSLS Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by ReShape Lifesciences Inc.

SEC Form SC 13D filed by ReShape Lifesciences Inc.

SEC Form SC 13D filed by ReShape Lifesciences Inc.

$RSLS SEC Filings

SEC Form PRER14A filed by ReShape Lifesciences Inc.

SEC Form PRE 14A filed by ReShape Lifesciences Inc.

SEC Form SCHEDULE 13G filed by ReShape Lifesciences Inc.

$RSLS Financials

Live finance-specific insights

ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update

$RSLS Leadership Updates

Live Leadership Updates

ReShape Lifesciences Appoints Seasoned Sales and Marketing Executive, Nick Ansari, as Senior Vice President of Global Commercial Operations

ReShape Lifesciences Announces Appointment of Paul F. Hickey as President and Chief Executive Officer

ReShape Lifesciences Strengthens Leadership Team with Appointment of Michael Bordainick as Senior Vice President, Commercial Operations

$RSLS Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Maxim Group initiated coverage on Reshape Lifesciences with a new price target

$RSLS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Stankovich Thomas sold $39 worth of shares (172 units at $0.23), decreasing direct ownership by 0.75% to 22,777 units (SEC Form 4)

New insider Schneid Yair claimed ownership of 2,461,000 shares (SEC Form 3)

Stankovich Thomas sold $386 worth of shares (435 units at $0.89), decreasing direct ownership by 2% to 22,949 units (SEC Form 4)

Recent Analyst Ratings for
$RSLS

$RSLS
Press Releases

$RSLS
Large Ownership Changes

$RSLS
SEC Filings

$RSLS
Financials

$RSLS
Leadership Updates

$RSLS
Analyst Ratings

$RSLS
Insider Trading